NTRK3 and cancer: Pan-TRK IHC is rapid and inexpensive, but it is unable to distinguish between WT and chimeric TRK protein and its sensitivity with respect to TRKC fusion proteins may be low (48); thus, it may be used as a screen to identify potential cancers with a low incidence of NTRK gene fusions that will require subsequent confirmatory tests (48).